# Alector, Inc. stock analysis

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheime

## Market evidence and data freshness

The public preview recorded Alector, Inc. at 2.045 USD on 2026-11-05T19:09:09.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2021-11-08 through 2026-11-03 across 1246 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

## What should I review before buying Alector, Inc. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

## Inside the full report

- Valuation
- Growth
- Financial health
- Ownership
- Research

Sign in to open the full analysis. Paid plans use included reports first, then your weekly usage limit. Access lasts 72 hours, including revisits.

[Read the report](https://commonquant.ai/markets/alec)